{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05662306",
            "orgStudyIdInfo": {
                "id": "20211098"
            },
            "organization": {
                "fullName": "University of Miami",
                "class": "OTHER"
            },
            "briefTitle": "C-Cog in Early Course Schizophrenia Study",
            "officialTitle": "Comprehensive Treatment of Early Course Schizophrenia: A Nonrandomized Study of Long Acting Injectable Antipsychotic Medication Combined With Cognitive and Functional Skills Training",
            "therapeuticArea": [
                "Mental Health"
            ],
            "study": "c-cog-in-early-course-schizophrenia-study"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-03",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-01-23",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-05-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-07-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-12-14",
            "studyFirstSubmitQcDate": "2022-12-14",
            "studyFirstPostDateStruct": {
                "date": "2022-12-22",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-03-11",
            "lastUpdatePostDateStruct": {
                "date": "2024-03-12",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Dante Durand",
                "investigatorTitle": "Associate Professor of Psychiatry",
                "investigatorAffiliation": "University of Miami"
            },
            "leadSponsor": {
                "name": "University of Miami",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Alkermes, Inc.",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to examine the role of clinical stability in functional recovery. in first episode schizophrenia."
        },
        "conditionsModule": {
            "conditions": [
                "Schizophrenia"
            ],
            "keywords": [
                "Relapse",
                "Remission",
                "Recovery"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE4"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 60,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Aripiprazole and Computerized Cognitive and Functional Skills Training Group",
                    "type": "EXPERIMENTAL",
                    "description": "Participants in this arm will receive long-acting injectable aripiprazole every 2 months formulation for 12 consecutive months. Participants in this arm will also receive Computerized cognitive and functional skills training during the first 12 weeks of study participation.",
                    "interventionNames": [
                        "Drug: Aripiprazole Lauroxil",
                        "Behavioral: Computerized cognitive and functional skills training"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Aripiprazole Lauroxil",
                    "description": "1064 mg 2-month long-acting injectable administered as an intramuscular injection over a 12-month period.",
                    "armGroupLabels": [
                        "Aripiprazole and Computerized Cognitive and Functional Skills Training Group"
                    ]
                },
                {
                    "type": "BEHAVIORAL",
                    "name": "Computerized cognitive and functional skills training",
                    "description": "Self-administered cognitive and technology focused skills training, administered at home for 2 hours per week for the first 12 weeks of the 12-month study period.",
                    "armGroupLabels": [
                        "Aripiprazole and Computerized Cognitive and Functional Skills Training Group"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "The percentage of participants who develop sustained remission of symptoms of schizophrenia as measured as having a score of 3 or less on all 6 critical items from the Positive and Negative Syndrome Scale (PANSS)",
                    "description": "PANSS has 6 critical items with each item being scored from 1 to 7 with the higher score indicating more severe symptoms. A score of 3 or less on all six critical items defines the presence of remission.",
                    "timeFrame": "6 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Adults\n2. Diagnosis of schizophrenia\n3. Current Hospitalization or outpatient relapse\n4. Fewer than four previous admissions\n5. Willing to accept long-acting injectable treatment and participate in rehabilitation\n\nExclusion Criteria:\n\n1. Primary diagnosis other than schizophrenia\n2. Prior Long Acting Injectable treatment\n3. Current Suicide Risk\n4. Hypersensitivity to Aripiprazole\n5. Pregnancy\n6. Positive illicit drug screen other than cannabis (rescreening allowed in 4 weeks for drug positive cases)\n7. Unable to give personal informed consent\n8. History of treatment resistance as evidenced by clozapine treatment\n9. Unable to stop treatment with medications that are strong Cytochrome (CYP) 2D6 or CYP 3A4 inhibitors and or strong CYP3A4 inducers (2.3, 7.1) for at 14 days prior to initiation.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Dante Durand, MD",
                    "role": "CONTACT",
                    "phone": "305-355-8237",
                    "email": "ddurand@med.miami.edu"
                },
                {
                    "name": "Gabriela Vargas, MBA",
                    "role": "CONTACT",
                    "phone": "305 243 2708",
                    "email": "gvargas3@med.miami.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Dante Durand, MD",
                    "affiliation": "University of Miami Miller School",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Jackson Memorial Hospital",
                    "status": "RECRUITING",
                    "city": "Miami",
                    "state": "Florida",
                    "zip": "33136",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Dante Durand, MD",
                            "role": "CONTACT",
                            "phone": "305-355-8237",
                            "email": "ddurand@med.miami.edu"
                        },
                        {
                            "name": "Dante Durand, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Philip Harvey, PhD",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 25.77427,
                        "lon": -80.19366
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000012559",
                    "term": "Schizophrenia"
                }
            ],
            "ancestors": [
                {
                    "id": "D000019967",
                    "term": "Schizophrenia Spectrum and Other Psychotic Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M15376",
                    "name": "Schizophrenia",
                    "asFound": "Schizophrenia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M21838",
                    "name": "Schizophrenia Spectrum and Other Psychotic Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000068180",
                    "term": "Aripiprazole"
                },
                {
                    "id": "C000603935",
                    "term": "Aripiprazole lauroxil"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000928",
                    "term": "Antidepressive Agents"
                },
                {
                    "id": "D000011619",
                    "term": "Psychotropic Drugs"
                },
                {
                    "id": "D000014150",
                    "term": "Antipsychotic Agents"
                },
                {
                    "id": "D000014149",
                    "term": "Tranquilizing Agents"
                },
                {
                    "id": "D000002492",
                    "term": "Central Nervous System Depressants"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018491",
                    "term": "Dopamine Agonists"
                },
                {
                    "id": "D000015259",
                    "term": "Dopamine Agents"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000058825",
                    "term": "Serotonin 5-HT1 Receptor Agonists"
                },
                {
                    "id": "D000017366",
                    "term": "Serotonin Receptor Agonists"
                },
                {
                    "id": "D000018490",
                    "term": "Serotonin Agents"
                },
                {
                    "id": "D000058830",
                    "term": "Serotonin 5-HT2 Receptor Antagonists"
                },
                {
                    "id": "D000012702",
                    "term": "Serotonin Antagonists"
                },
                {
                    "id": "D000065127",
                    "term": "Dopamine D2 Receptor Antagonists"
                },
                {
                    "id": "D000018492",
                    "term": "Dopamine Antagonists"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M229",
                    "name": "Aripiprazole",
                    "asFound": "Massage",
                    "relevance": "HIGH"
                },
                {
                    "id": "M16904",
                    "name": "Antipsychotic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M238844",
                    "name": "Aripiprazole lauroxil",
                    "asFound": "Subcutaneous heparin",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4247",
                    "name": "Antidepressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M14474",
                    "name": "Psychotropic Drugs",
                    "relevance": "LOW"
                },
                {
                    "id": "M7473",
                    "name": "Dopamine",
                    "relevance": "LOW"
                },
                {
                    "id": "M20595",
                    "name": "Dopamine Agonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M17962",
                    "name": "Dopamine Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M15512",
                    "name": "Serotonin",
                    "relevance": "LOW"
                },
                {
                    "id": "M29240",
                    "name": "Serotonin 5-HT1 Receptor Agonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M19648",
                    "name": "Serotonin Receptor Agonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20596",
                    "name": "Dopamine Antagonists",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "PsychDr",
                    "name": "Psychotropic Drugs"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "CaAg",
                    "name": "Cardiotonic Agents"
                }
            ]
        }
    },
    "hasResults": false
}